Literature DB >> 35935925

Gadolinium Deposition Disease: A Case Report and the Prevalence of Enhanced MRI Procedures Within the Veterans Health Administration.

D Bradley Jackson1,2, Terence MacIntyre1, Vianey Duarte-Miramontes1, Joshua DeAguero1,2,3, G Patricia Escobar1,2,3, Brent Wagner1,2,3.   

Abstract

Background: Gadolinium (Gd) usage in the Veterans Health Administration is increasing and patients with renal disease are frequently exposed. Gd is not entirely eliminated within 24 hours after administration, which may pose long-term adverse effects. Case Presentation: A Vietnam-era veteran aged > 70 years presented for evaluation of Gd-based contrast agent-induced chronic multisymptom illness. In the course of his routine clinical care, he was exposed to repeated Gd-enhanced magnetic resonance imaging studies. After his second Gd-based contrast agent exposure, he noted rash, pain, headaches, and hoarseness. Years after the exposure to the contrast agents, he continued to have detectable Gd in urine and serum. Conclusions: Practitioners should be aware of long-term intracellular Gd retention (including the brain) as patients increasingly turn to consultants with concerns about Gd deposition disease. Data from patient advocates demonstrate that Gd is eliminated in intermediate and long phases, which may represent a multicompartment model. The commercialization of Gd use in imaging studies is outpacing the science addressing the long-term consequences of harboring this alien, toxic, nonphysiologic rare earth metal.
Copyright © 2022 Frontline Medical Communications Inc., Parsippany, NJ, USA.

Entities:  

Year:  2022        PMID: 35935925      PMCID: PMC9351733          DOI: 10.12788/fp.0258

Source DB:  PubMed          Journal:  Fed Pract        ISSN: 1078-4497


  41 in total

Review 1.  Gadolinium-based contrast agents: why nephrologists need to be concerned.

Authors:  Katarina Leyba; Brent Wagner
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-03       Impact factor: 2.894

2.  Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema.

Authors:  Cynthia Kucher; Xiaowei Xu; Theresa Pasha; Rosalie Elenitsas
Journal:  J Cutan Pathol       Date:  2005-08       Impact factor: 1.587

3.  Gadolinium chloride toxicity in the rat.

Authors:  A J Spencer; S A Wilson; J Batchelor; A Reid; J Rees; E Harpur
Journal:  Toxicol Pathol       Date:  1997 May-Jun       Impact factor: 1.902

Review 4.  Nephrogenic fibrosing dermopathy in a patient with acute renal failure never requiring dialysis.

Authors:  Tamella B Cassis; James Mark Jackson; George B Sonnier; Jeffrey P Callen
Journal:  Int J Dermatol       Date:  2006-01       Impact factor: 2.736

Review 5.  Exposure, metabolism, and toxicity of rare earths and related compounds.

Authors:  S Hirano; K T Suzuki
Journal:  Environ Health Perspect       Date:  1996-03       Impact factor: 9.031

6.  Type of MRI contrast, tissue gadolinium, and fibrosis.

Authors:  Catherine Do; Jeffrey L Barnes; Chunyan Tan; Brent Wagner
Journal:  Am J Physiol Renal Physiol       Date:  2014-08-06

7.  Gray Matter Nucleus Hyperintensity After Monthly Triple-Dose Gadopentetate Dimeglumine With Long-term Magnetic Resonance Imaging.

Authors:  John J DeBevits; Reshma Munbodh; Devin Bageac; Rong Wu; Paul A DiCamillo; Chaoran Hu; Lihong Wang; Robert T Naismith; David Karimeddini; Suhayl Dhib-Jalbut; Sviatoslav Redko; Stuart D Cook; Diego Cadavid; Leo Wolansky
Journal:  Invest Radiol       Date:  2020-10       Impact factor: 6.016

8.  Gadolinium-based contrast agents - what is the evidence for 'gadolinium deposition disease' and the use of chelation therapy?

Authors:  Kerry A Layne; David M Wood; Paul I Dargan
Journal:  Clin Toxicol (Phila)       Date:  2019-10-30       Impact factor: 4.467

Review 9.  Gadolinium-Based Contrast Agent Use, Their Safety, and Practice Evolution.

Authors:  Catherine Do; Joshua DeAguero; Adrian Brearley; Xochitl Trejo; Tamara Howard; G Patricia Escobar; Brent Wagner
Journal:  Kidney360       Date:  2020-06-25

10.  Physicians with self-diagnosed gadolinium deposition disease: a case series.

Authors:  Richard C Semelka; Miguel Ramalho
Journal:  Radiol Bras       Date:  2021 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.